HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ribavirin (Virazole)

A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.
Also Known As:
Virazole; Ribasphere; ICN-1229; Rebetol; Ribamide; Ribamidil; Ribamidyl; Vilona; Viramide; Virazide; ICN 1229; ICN1229; Ribovirin; Tribavirin; 1H-1,2,4-Triazole-3-carboxamide, 1-beta-D-ribofuranosyl-
Networked: 8673 relevant articles (1279 outcomes, 1552 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1. Zeuzem, Stefan: 137 articles (01/2021 - 12/2002)
2. McHutchison, John G: 93 articles (01/2019 - 03/2002)
3. Kumada, Hiromitsu: 78 articles (01/2020 - 01/2002)
4. Marcellin, Patrick: 73 articles (10/2020 - 01/2002)
5. Shiffman, Mitchell L: 71 articles (12/2019 - 09/2002)
6. Pol, Stanislas: 69 articles (10/2020 - 07/2002)
7. Chayama, Kazuaki: 66 articles (12/2020 - 01/2006)
8. Ferenci, Peter: 63 articles (03/2018 - 11/2002)
9. Lawitz, Eric: 62 articles (10/2020 - 08/2008)
10. Sulkowski, Mark S: 62 articles (01/2020 - 11/2002)

Related Diseases

1. Chronic Hepatitis C
2. Infections
3. Hepatitis C
4. Fibrosis (Cirrhosis)
12/01/2006 - "Thus, (1) patients with genotypes 2 and 3 and severe fibrosis can be treated with low dose of Peg-IFN and ribavirin, (2) this study suggests that patients with genotypes 1, 4 and 5 and high viraemia could receive a standard dose of Peg-IFN associated with ribavirin for 48 weeks, (3) side effects limit the efficacy of the treatment with standard dose of Peg-IFN in patients with genotypes 1, 4 and 5 and low viraemia, (4) more studies are needed for patients with genotype 2 or 3 to define the optimal duration (24 or 48 weeks) in patients with severe fibrosis."
08/01/2015 - "Ribavirin is required only for some treatment regimens and may be particularly beneficial in patients with cirrhosis. "
04/01/2000 - "Although current evidence suggests that the combination of ribavirin and IFN-alpha might be more efficacious than IFN alone in increasing the response rate in patients in the advanced fibrotic stage, the efficacy of this regimen for patients with well-compensated HCV-related cirrhosis is still unknown and prospective well-designed studies are urgently needed. "
06/27/2022 - "While the addition of ribavirin (RBV) to SOF/VEL improved sustained virological response (SVR12) in genotype 3 (GT3) decompensated cirrhosis patients, the benefits of RBV in GT3 compensated cirrhosis patients receiving SOF/VEL remains unclear. "
03/01/2005 - "A recent clinical trial of peginterferon alpha-2a plus ribavirin in African American patients resulted in a higher SVR rate, 26%, than observed previously, and 90% of patients showed stabilization or improvement in fibrosis. "
5. Virus Diseases (Viral Diseases)

Related Drugs and Biologics

1. Interferons
2. Antiviral Agents (Antivirals)
3. Interferon-alpha (Interferon Alfa)
4. Sofosbuvir
5. Protease Inhibitors (Protease Inhibitor)
6. telaprevir
7. Ritonavir (Norvir)
8. paritaprevir
9. ombitasvir
10. N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamide

Related Therapies and Procedures

1. Therapeutics
2. Liver Transplantation
3. Retreatment
4. Aftercare (After-Treatment)
5. Duration of Therapy